Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Ramucirumab
Related studies linked through entity extraction aliases.
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis
- Status
- COMPLETED
- Phase
- PHASE2
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE2